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Abstract 
Purpose of review: 
Genetic, epigenetic and expression analyses have refined the traditional, 
histopathology based classification of diffusely infiltrating gliomas. This 
review summarizes these trends and implications for elderly patients. 
Recent findings: 
The vast majority of diffusely infiltrating gliomas in elderly patients share an 
unfavorable molecular phenotype, i.e. TERT promoter mutation in the absence 
of IDH mutation and 1p/19q co-deletion. Histopathologically, these are mostly 
astrocytic tumors and treatment is guided by the methylation status of the O6-
methylguanine-DNA-methyltransferase (MGMT) promoter. 1p/19q co-deletion 
indicates oligodendroglial histology and benefit from the addition of PCV 
(procarbazine, CCNU/lomustine, vincristine) polychemotherapy to 
radiotherapy. These tumors are almost exclusively associated with IDH 
mutations, but their molecular profile is rare in elderly patients. Two large 
phase III trials, RTOG 0825 and AVAGlio, failed to demonstrate an overall 
survival benefit from anti-angiogenic therapy with bevacizumab added to 
combined chemoradiotherapy in patients with newly diagnosed glioblastoma, 
but a trend towards improved survival with increasing age can be noted. 
Ongoing clinical trials in elderly patients with diffusely infiltrating glioma will 
clarify the role of combined chemoradiotherapy, and of bevacizumab or other 
anti-angiogenic agents as an adjunct to radiotherapy. 
 3 
Summary: 
The choice of firstline therapy in elderly patients with diffusely infiltrating 
glioma is between post-operative hypofractionated radiotherapy and/or 
chemotherapy, guided by MGMT methylation in most patients. 
Keywords: IDH, MGMT, elderly, glioma 
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Introduction  
The current diagnosis of gliomas is based on histopathologic features according 
to the World Health Organisation (WHO) classification of primary brain 
tumors1. Diffusely infiltrating gliomas are assigned to WHO grades II-IV and 
further classified based on their lineage differentiation as astrocytic or 
oligodendroglial. Assignment of WHO grade IV is confined to glioblastoma 
and its variants, which are characterized by mostly astrocytic differentiation, 
microvascular proliferation and necrosis1. In elderly patients aged 65 years or 
older, glioblastoma (WHO grade IV) accounts for 83.8% of new diagnoses of 
diffusely infiltrating gliomas, followed by diffuse astrocytoma (7.5%, WHO 
grade II) and anaplastic astrocytoma (5.8%, WHO grade III)2. However, the 
prognostic significance of histopathological classification is limited in the 
elderly population. Among patients aged 65-74 years, 1-year survival rates are 
36.9% (95% CI: 33.1-40.6) for diffuse astrocytoma, 33.2% (95% CI: 29.0-
37.3) for anaplastic astrocytoma and 25.3% (95% CI: 24.3-26.3) for 
glioblastoma2. Consequently, watchful waiting strategies advocated for WHO 
grade II tumors in younger patients are not feasible in the elderly population3, 4. 
Recently, progress in the molecular characterization of gliomas led to the 
identification of a panel of prognostic markers and a novel classification of 
prognostic entities based on the occurrence of isocitrate dehydrogenase (IDH) 
1 or 2 mutations, co-deletions of chromosome arms 1p/19q, and mutations in 
the promoter region of the gene encoding telomerase reverse transcriptase 
(TERT) 5-7: (i) co-occurrence of mutant IDH and 1p/19q co-deletions is usually 
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accompanied by TERT promoter mutations5-7 and almost exclusively confined 
to WHO grade II/III tumors with oligodendroglial histology8, 9. These tumors 
are associated with the most favorable prognosis5, 10-12, (ii) IDH mutant, 1p/19q 
non-co-deleted tumors do not usually have TERT mutations5-7 and are 
characterized by tumor suppressor gene TP53 mutations, often accompanied by 
mutations in the alpha thalassemia/mental retardation syndrome X-linked 
(ATRX) gene8, 9. Histologically, these are mostly astrocytic tumors8, 9 and the 
prognosis is intermediate5, 10-12. (iii) IDH wild-type tumors are mostly 
astrocytic tumors with mutant TERT and lack 1p/19q co-deletions6, 7. IDH 
wild-type tumors are associated with poor prognosis and comprise the majority 
of elderly patients with diffusely infiltrating glioma13. Integrated analyses of 
genetic, epigenetic, gene expression and microRNA expression data 
complement evidence that diffuse gliomas in the elderly are genetically distinct 
from gliomas in younger patients5, 13-15. However, these advances in classifying 
gliomas have not yet been integrated in population-based epidemiological 
studies.  
The incidence of astrocytic diffusely infiltrating gliomas increases with age, 
whereas oligodendroglial tumors are rare in elderly patients (Table 1)2. 
Considering the constantly increasing life expectancy in most societies around 
the world, the number of elderly patients with diffusely infiltrating glioma will 
grow. Yet, only few randomized clinical trials in elderly patients have been 
completed16-19. The particular paucity of data available to guide the treatment 
of elderly patients with WHO grade II gliomas as well as the comparable 
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prognosis and molecular similarities with WHO grade III/IV tumors may 
justify analogous treatment in most cases (Figure 1). 
Concerns to enroll elderly patients with diffuse glioma into clinical trials 
include higher morbidity, reduced treatment tolerability and impairment of 
quality of life due to toxicity. However, evidence from several trials 
demonstrated that treatment of elderly patients with glioblastoma yielded stable 
or improved quality of life until progression16, 17, 20. Treatment modalities for 
diffusely infiltrating glioma comprise the classical triad of cancer therapeutics, 
i.e. surgery, radiotherapy and chemotherapy, but further individualizing 
treatments by targeting the molecular mechanisms that drive the malignant 
phenotype in elderly patients will ultimately improve outcome. 
 
Biopsy or Surgery? 
Microsurgical resection or diagnostic biopsy is required for establishing the 
histopathologic diagnosis and should precede any further treatment. The 
therapeutic value of microsurgical resection is under debate, because 
sufficiently powered randomized trials in the elderly are lacking. While 
retrospective studies suggest that maximum safe resection improves survival 
compared to biopsy in patients with WHO grade II gliomas3, 21, 22, elderly 
patients are generally underrepresented in these cohorts. However, 
accumulating evidence suggests that maximum safe resection improves 
survival in elderly patients with WHO grade III/IV gliomas: Among 372 
 7 
patients >65 years that were treated for anaplastic astrocytoma or glioblastoma 
within the NOA-08 trial, extent of resection was an independent prognostic 
factor in a pre-specified survival model that controlled for age, O6-
methylguanine-DNA methyltransferase (MGMT) promoter methylation, study 
treatment and histology18. In a case-control study including 80 patients over 65 
years that were matched for age, KPS, tumor location and adjuvant therapies, 
an overall survival benefit for surgery versus biopsy (5.7 vs 4.0 months, 
p=0.02) was apparent23. These results are further supported by a retrospective 
study in 142 patients with newly diagnosed glioblastoma aged >65 years, 
among which resection versus biopsy was associated with prolonged survival 
(13.0 vs 4.0 months, p<0.001)24. Finally, biopsy versus surgical resection was 
associated with inferior overall survival (HR 1.50 [95% CI 1.17-1.92]) in 
multivariate analyses of the Nordic trial (N=342), which compared two 
different radiotherapy regimens and temozolomide in patients with newly 
diagnosed glioblastoma aged >60 years19. In contrast, one retrospective single 
center cohort study of 58 patients aged >80 failed to demonstrate prolonged 
survival of a sub-group of 12 patients that underwent gross total resection, as 
compared to incomplete resection or biopsy25, but the small sample size of this 
cohort longs for further evaluation of the value of extent of resection in this 
particularly old subgroup of patients.  
 
Radiotherapy or chemotherapy – or both? 
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The European Organisation for Research and Treatment of Cancer (EORTC) 
22981/26981 / National Cancer Institute of Canada (NCIC) CE.3 trial has 
defined combined chemoradiotherapy to 30 x 2 = 60 Gray (Gy) with daily 
concomitant TMZ at 75 mg/m2 followed by 6 cycles of TMZ at 150-200 mg/m2 
on 5/28 days as the standard of care for glioblastoma26, 27. Combined 
chemoradiotherapy prolonged median overall survival by 2.4 months compared 
to radiotherapy alone (HR 0.63, 95% CI 0.52-0.75, P<0.001)26. However, the 
trial did not enroll patients older than 70 years and post-hoc analyses suggested 
decreased efficacy of the addition of TMZ to RT in patients aged 66-70 years 
(HR 0.78, 95% CI 0.50-1.25, p=0.29)28, but the trial was not powered for age 
stratified efficacy analyses. The efficacy of combined chemoradiotherapy 
versus radiotherapy alone in elderly patients aged over 65 years with newly 
diagnosed glioblastoma and good clinical performance is currently being 
evaluated by an international NCIC/EORTC phase III trial (NCT00482677). 
 
Radiotherapy 
The efficacy of post-surgical radiotherapy (RT) in elderly patients with 
glioblastoma or anaplastic astrocytoma was demonstrated by a randomized trial 
of the Association des Neuro-Oncologues d‘Expression Francaise 
(ANOCEF)16. A total of 81 patients aged 70 years or older with a KPS of at 
least 70% were randomized to receive best supportive care (BSC) with RT of 
contrast-enhancing tumor and a 2 cm margin to 50 Gy in fractions of 1.8 Gy, or 
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BSC alone. RT prolonged survival approximately two fold without major 
impact on quality of life or mental status16. A population-based retrospective 
review of 2836 elderly patients with glioblastoma (median aged 76.9 years 
[range 71-98]) demonstrated a survival benefit from RT too, after adjusting for 
tumor size, tumor location, surgery and demographics (HR 0.43, 95% CI 0.38-
0.49)29.  
Standard RT for glioblastoma is 54–60 Gy given in 1.8–2 Gy fractions27 and 
thus requires daily traveling during 6 weeks, which may be a particular burden 
for elderly patients with eminent morbidity. In a randomized trial in patients 
with glioblastoma aged 60 years or older (N=95), standard RT of 30 x 2 = 60 
Gy (mean age 72.4 years) versus hypofractionated RT of 15 x 2.66 = 40 Gy 
(mean age 71.0 years) yielded similar median survival from the time of 
diagnosis (6.1 versus 5.9 months, HR 0.90 [95% CI 0.60-1.35], p=0.61)17. 
These results were complemented by subgroup analyses of the phase III Nordic 
trial, which randomised 291 elderly patients (>60 years) with glioblastoma to 
three different treatment arms, including TMZ dosed to 150-200 mg/m2 on 
5/28 days, standard RT of 30 x 2 = 60 Gy and hypofractionated RT of 10 x 3.4 
= 34 Gy19. Comparing hypofractionated RT and standard RT within the 
intention to treat (ITT) population among the subgroup of patients aged 70 
years or older (N=81), hypofractionated RT improved overall survival versus 
standard RT (7.0 vs 5.2 months, p=0.02), presumably in part because a 
substantial fraction of patients did not complete the entire course of standard 
RT19. These trials were not powered to demonstrate the efficacy of both RT 
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regimens, but, for pragmatic reasons, hypofractionated RT has become the 
preferred regimen for elderly patients and patients in poor general condition, 
across WHO grades27. Of note, accelerated and lower dose RT is also an option 
for the therapy of patients with WHO grade II gliomas30, but no data 
particularly evaluating its role in elderly patients are available.  
 
Temozolomide 
Among the ITT population of the Nordic trial (N=291), TMZ (N=93) was as 
efficient as hypofractionated RT (N=98) (HR 0.82 [96% CI 0.63-1.06]) in a 
survival model that controlled for age, type of surgery (biopsy versus resection) 
and WHO performance score 19. In parallel, the German NOA-08 trial 
evaluated TMZ as an alternative to RT in elderly patients with glioblastoma 
(89%) or anaplastic astrocytoma (11%). The NOA-08 trial enrolled 412 of 584 
screened patients aged 65 years or older with a KPS over 60%, of which 373 
patients received at least one dose of treatment to be included in efficacy 
analyses18. RT was administered to 30 x 2 = 60 Gy and TMZ was administered 
at a dose-dense schedule of 100 mg/m2 given on days 1–7 every other week (1 
week on/1 week off). In a survival model that controlled for age, histological 
diagnosis, extent of resection and MGMT promoter methylation, the effect of 
dose-dense TMZ on overall survival was non-inferior to standard RT (HR 1.09 
[95% CI 0.84–1.42]) and overall survival rates after 12 months were 34.4% 
(95% CI 27.6–41.4) in the TMZ group and 37.4% (95% CI 30.1–44.7) in the 
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RT group18. The comparable results from the Nordic and NOA-08 trials with 
two different TMZ dosing regimens have yielded standard 5/28 the preferred 
dosing regimen in elderly patients27, because no additional benefit was noted 
from dose-intensified TMZ in patients with anaplastic astrocytoma and 
glioblastoma, while toxicity was enhanced18, 31.  
In patients aged 70 years or younger, benefit from TMZ was mainly restricted 
to patients with hypermethylation of the promoter region of MGMT32. To 
evaluate whether this accounts for elderly patients, too, survival analyses 
stratified for MGMT methylation status were included in the Nordic and NOA-
08 trials18, 19. In both trials MGMT methylation predicted benefit from TMZ, 
and a trend towards inferior survival with TMZ among unmethylated patients 
was noted (Table 2).  
In a retrospective analysis of pooled data from patients assessed within the 
NOA-04 and NOA-08 trials, and the German Glioma Network, IDH mutation 
assessment refined the predictive role of MGMT promoter methylation status 
for benefit from TMZ in patients with anaplastic gliomas33. Further, long-term 
follow-up data of two phase III trials in patients with anaplastic 
oligodendroglial gliomas (EORTC 26951 and RTOG 9402) defined 1p/19q co-
deletion as a strong predictor for benefit from polychemotherapy with 
procarbazine, lomustine (CCNU) and vincristine (PCV) 10, 11. Yet, assessment 
of IDH mutation status or 1p/19q deletions in elderly patients is not part of 
clinical routine, because both these markers are rare in elderly patients with 
diffusely infiltrating gliomas27 and because toxicity from PCV likely limits its 
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utility in elderly patients. Further, TMZ and PCV were similarly active in 
patients with anaplastic gliomas treated in the NOA-04 trial12, and therefore, 
TMZ is advocated as a less toxic alternative to PCV in elderly patients, 
although a sufficiently powered clinical trial that directly compares PCV versus 
TMZ in diffusely infiltrating gliomas with 1p/19q co-deletion is lacking. In 
patients with WHO grade II gliomas, benefit from temozolomide is predicted 
by 1p/19q co-deletion34, mutant IDH 35, and methylated MGMT36, but the role 
in elderly patients is elusive due to the low frequency of these tumors in 
patients aged over 65 years2. Of note, 1p/19q co-deletion and mutant IDH were 
not prognostic in a cohort of mostly WHO grade II gliomas that were not 
treated with radio- or chemotherapy37, 38.  
In summary, the Nordic and NOA-08 trials defined a predictive role of MGMT 
promoter methylation for benefit from TMZ, but not RT, and have thereby 
defined MGMT testing as standard of care in elderly patients with glioblastoma 
and anaplastic astrocytoma (Figure 1)27. The optimal combination of RT and 
TMZ for adults of any age with anaplastic gliomas that lack 1p/19q co-
deletions is currently being evaluated by the EORTC trial CATNON 
(NCT00626990).  
 
Is anti-angiogenic treatment an alternative to chemo- or radiotherapy? 
Two independent placebo-controlled phase III trials (AVAglio and RTOG 
0825) have demonstrated improved progression-free survival, but no overall 
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survival benefit from the addition of the humanized anti-vascular endothelial 
growth factor (VEGF) antibody bevacizumab (BEV) to standard combined 
chemoradiotherapy (RT/TMZTMZ 5/28) in patients with newly diagnosed 
glioblastoma39, 40. The RTOG-0825 trial randomized 637 patients with a 
median age of 58 years (range: 19-82) in mostly good general condition (KPS 
90-100: N=378, 60.9%)40. Among 921 patients randomized in the AVAglio 
trial, the median age was 57 years (range: 18-84), including 369 (40.1%) aged 
60 years or older and 630 patients (68.7%) had a KPS of 90 or 100. On 
univariate analyses, a trend toward improvement of overall survival was noted 
with increasing age, though not reaching statistical significance (Table 3). Of 
note, the RTOG 0825 and AVAGlio trials were not powered to evaluate the 
age-stratified efficacy of BEV, but two early uncontrolled trials41, 42 and one 
retrospective study43 suggested increased benefit from BEV among elderly 
patients, too and this appeared to account particularly for patients with poor 
general condition42, 43. However, this population was likely underrepresented in 
the AVAGlio and RTOG-0825 trials, because good general condition 
(KPS>60) was an inclusion criterion in both trials 39, 40. Currently, the 
randomized phase II Avastin plus radiotherapy in elderly patients with 
glioblastoma (ARTE) trial is exploring outcomes in patients aged 65 or older 
with newly diagnosed, MGMT unmethylated glioblastoma treated with 
hypofractionated RT (15 x 2.66 = 40 Gy) with or without additional BEV 
(NCT01443676).  
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Therapeutic options at progression 
To date, no controlled trials specifically evaluating treatment options for 
elderly patients with recurrent diffusely infiltrating glioma have been 
conducted. Treatment options include monotherapies or combined regimens 
containing temozolomide, nitrosoureas (in particular CCNU/lomustine) and 
bevacizumab, dependent on patient and tumor characteristics, pretreatment, 
availability and local preferences44. Based on uncontrolled trials, only patients 
in good general condition where gross total resection is safely feasible should 
be considered for repeat surgery27 and repeat RT should only be considered in 
patients with KPS >60, small tumors and time of progression over 6 months 
from surgery when chemotherapy is contraindicated45. However, patterns of 
progression and comorbidities mostly preclude repeat surgery and repeat RT as 
an option for elderly patients. 
Treatment choice at recurrence is particularly challenging in the majority of 
elderly patients with MGMT unmethylated tumors that were pretreated with 
hypofractionated RT, because the efficacy of alkylating chemotherapy is very 
limited. The Dutch BELOB trial explored the efficacy of lomustine versus 
bevacizumab versus a combination of both in 153 patients with recurrent 
glioblastoma at a median age of 57 years46. Although age-stratified survival 
analyses were not included in the publication, good treatment tolerability and 
favorable survival in the combination group versus bevacizumab mono-therapy 
versus lomustine mono-therapy (median post recurrence survival: 12 vs 8 vs 8 
months) suggest that the combination of BEV and lomustine may be a valid 
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option for elderly patients with recurrent disease. Of note, no difference in 
overall survival was detected in MGMT stratified analyses of 43 patients 
treated with lomustine alone (HR unmethylated versus methylated: 0.89 [95% 
CI: 0.48-1.64]) and addition of lomustine to BEV in patients with unmethylated 
MGMT increased overall survival rates at 9 months from 12% (95% CI: 3-29) 
for BEV alone to 58% (95% CI: 37-74) for the combination of BEV and 
lomustine46, thus suggesting some activity of lomustine in MGMT 
unmethylated glioblastoma. Whether lomustine is active in elderly patients, 
too, remains to be explored. Stratification by age <50 versus 50+ years 
demonstrated no difference in the efficacy of lomustine in a recent phase III 
trial for recurrent glioblastoma, which utilized lomustine as standard therapy in 
92 patients yielding a 19% progression free survival rate at 6 months47. 
However, median age or MGMT methylation status was not reported and a 
majority of included patients had a good KPS of 90-100%, thus limiting 
extrapolations on a frail elderly population.  
Hypofractionated RT at recurrence is the treatment of choice for elderly 
patients with methylated MGMT promoter that received first line therapy with 
TMZ12, 18. TMZ re-challenge may also be considered after a TMZ-free interval 
in patients that responded to first line TMZ, i.e. essentially patients with 
MGMT methylated tumors48. Standard dosing at 150-200 mg/m2 on 5/28 days 
is preferred27, since dose-intensified TMZ regimens are unlikely to be more 
active at rechallenge31, 49.  
However, randomized trials evaluating treatment options for elderly patients 
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with recurring diffusely infiltrating glioma are required to define a standard of 
care. 
 
Conclusion 
Diffusely infiltrating gliomas in elderly patients differ molecularly from their 
histopathological counterparts in younger patients. Favorable molecular 
markers including mutant IDH and 1p/19q co-deletions are rare among elderly 
patients. Considering molecular similarities, poor prognosis and paucity of 
available data, we advocate to treat WHO grade II gliomas in elderly patients 
analogous to WHO grade III/IV gliomas if IDH wild-type status is confirmed. 
MGMT promoter methylation predicts benefit from TMZ and should therefore 
be determined in elderly patients with diffusely infiltrating glioma to guide first 
line treatment (Figure 1). Treatment options at recurrence are limited and 
generally lack evidence from randomized controlled trials. Future clinical trials 
focusing on the distinct molecular profile of diffusely infiltrating gliomas in the 
elderly should be conducted for both first and second line treatments. 
 
• A novel prognostic classification of diffusely infiltrating gliomas has 
been suggested based on the presence of IDH mutation, chromosome 
1p/19q co-deletion and TERT promoter mutations. 
• Diffusely infiltrating gliomas in elderly patients are characterized by the 
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least favorable combination of these markers, i.e. TERT promoter 
mutation in the absence of IDH mutation and 1p/19q co-deletion. 
• The mainstay of treatment in elderly patients is maximum safe resection 
followed by chemo- or radiotherapy. 
• MGMT promoter hypermethylation predicts response to alkylating 
chemotherapy in patients with newly diagnosed as well as recurrent glioblastoma . 
• There is a trend for benefit from anti-angiogenic treatment with 
bevacizumab with increasing age. 
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Figure legend 
Figure 1. Therapeutic approach to diffusely infiltrating gliomas in elderly 
patients. MGMT, O6-methylguanine-DNA methyltransferase; IDH, isocitrate 
dehydrogenase; TMZ, temozolomide; RT, radiotherapy. TMZ/RT, 30 x 2 = 60 
Gray (Gy) with daily concomitant temozolomide at 75 mg/m2; PCV, 
polychemotherapy with procarbazine, CCNU (lomustine) and vincristine. 
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Tables 
 
Table 1. Age-specific annual incidence of diffusely infiltrating gliomas (Central Brain Tumor Registry of the United States, statistical 
report 2007-2011) 2. 
  Age at diagnosis 
 WHO 
grade 
0-19 20-34 35-44 45-54 55-64 65-74 75-84 85+ 
Oligodendroglioma  II 0.05 (0.05 
– 0.06) 
0.31 (0.29 
– 0.33) 
0.47 (0.44 
– 0.50) 
0.42 (0.39 
– 0.44) 
0.32 (0.29 
– 0.34) 
0.22 (0.20 
– 0.26) 
0.20 (0.17 
– 0.24) 
0.10 (0.07 
– 0.15) 
Anaplastic 
oligodendroglioma 
III 0.05 (0.05 
– 0.06)  
0.31 (0.29 
– 0.33)  
0.47 (0.44 
– 0.50) 
0.42 (0.39 
– 0.44)  
0.32 (0.29 
– 0.34)  
0.22 (0.20 
– 0.26)  
0.20 (0.17 
– 0.24)  
0.10 (0.07 
– 0.15)  
Diffuse 
astrocytoma 
II 0.27 (0.26 
– 0.29) 
0.50 (0.48 
– 0.53) 
0.58 0.55 
– 0.61) 
0.61 (0.57 
– 0.64) 
0.79 (0.75 
– 0.83) 
1.02 (0.96 
– 1.08) 
1.14 (1.06 
– 1.23) 
0.68 (0.59 
– 0.79) 
Anaplastic 
astrocytoma 
III 0.09 (0.08-
0.10) 
0.28 (0.26-
0.30) 
0.39 (0.36-
0.41) 
0.46 (0.43-
0.48) 
0.65 (0.61-
0.69) 
0.90 (0.85-
0.96) 
0.92 (0.85-
0.99) 
0.39 (0.32-
0.47) 
Glioblastoma IV 0.15 (0.14-
0.17) 
0.41 (0.39-
0.43) 
1.23 (1.18-
1.28) 
3.59 (3.51-
3.67) 
8.03 (7.90-
8.16) 
13.09 
(12.87-
13.31) 
15.03 
(14.74-
15.34) 
8.95 (9.60-
9.32) 
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Table 2. Survival of elderly patients treated in the NOA-08 and Nordic trials: stratified by MGMT promoter methylation18, 19. 
 NOA-08: Age 65+, Radiotherapy 30 x 2 Gy versus 
Temozolomide on 7/14 days 100 mg/m2 
Nordic: Age 60+, Radiotherapy 10 x 3.4 Gy or 30 x 2 Gy 
versus Temozolomide 5/28 days 150-200 mg/m2 
 Methylated Unmethylated Methylated Unmethylated 
 RT, N=42 TMZ, 
N=31 
p RT, 
N=59 
TMZ, 
N=77 
p RT, 
N=63 
TMZ, 
N=28 
p RT, 
N=68 
TMZ, 
N=44 
p 
Median 
EFSa: months 
(95 % CI) 
4.6 (4.2–
5.0)  
8.4 (5.5-
11.7) 
- 4.6 (3.7–
6.3) 
3.3 
(3.0–
3.5) 
- - - - - - - 
Median OS: 
months (95 
% CI) 
9.6 (6.4- 
n.r.) 
n.r. - 10.4 (8.0-
11.6) 
7.0 
(5.7–
8.7) 
- 8.2 (6.6–
9.9)  
 
9.7 
(8.0–
11.4)  
 
- 7.0 (5.7–
8.3)  
 
6.8 
(5.9–
7.7)  
 
- 
HR for EFSa 
(95 % CI)b 
1.0c 0.53 
(0.33–
0.86) 
0.01 1.0c 1.95 
(1.41–
2.69) 
0.01 - - - - - - 
HR for OS 
(95 % CI)b 
1.0c 0.69 
(0.35–
1.16) 
0.14 1.0c 1.34 
(0.92–
1.95) 
0.13 1.0 0.64 
(0.39–
1.04)  
0.07 1.0 1.16 
(0.78–
1.72) 
0.46 
a event-free survival (EFS) or progression-free survival (PFS) were not reported in the Nordic trial; b NOA-08: Cox-regression model 
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correcting for age, extent of resection, histology and MGMT; Nordic: No multivariate analyses for EFS or PFS reported; Cox-
regression correcting for age, type of surgery (biopsy versus resection), WHO performance score and MGMT; c methylated and 
unmethylated tumors were pooled for reference (N=178). 
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Table 3. Age-stratified hazard ratios for overall survival of patients treated within the AVAGlio trial39. 
Age N HR (95% CI)a 
<50 229 1.05 (0.76-1.44) 
50-59 323 0.90 (0.70-1.16) 
60-69 296 0.81 (0.63-1.05) 
a univariate analyses in patients receiving combined radiochemotherapy plus bevacizumab versus placebo 
 
 
